321 related articles for article (PubMed ID: 22104451)
1. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Chrysant SG
Postgrad Med; 2011 Nov; 123(6):21-31. PubMed ID: 22104451
[TBL] [Abstract][Full Text] [Related]
2. The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension.
Huan Y; Townsend R
Expert Opin Pharmacother; 2012 Nov; 13(16):2409-15. PubMed ID: 23067322
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
4. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
Frampton JE; Scott LJ
Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.
de la Sierra A; Barrios V
Adv Ther; 2012 May; 29(5):401-15. PubMed ID: 22610686
[TBL] [Abstract][Full Text] [Related]
6. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
Deeks ED
Am J Cardiovasc Drugs; 2009; 9(6):411-8. PubMed ID: 19929039
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
Neutel J; Shojaee A; Maa JF
Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
[TBL] [Abstract][Full Text] [Related]
8. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.
Calhoun DA; Crikelair NA; Yen J; Glazer RD
Adv Ther; 2009 Nov; 26(11):1012-23. PubMed ID: 20024680
[TBL] [Abstract][Full Text] [Related]
9. Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.
Lewin AJ; Kereiakes DJ; Chrysant SG; Izzo JL; Oparil S; Lee J; Fernandez V; Melino M
Ethn Dis; 2014; 24(1):41-7. PubMed ID: 24620447
[TBL] [Abstract][Full Text] [Related]
10. Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination?
Barrios V; Escobar C
Expert Rev Cardiovasc Ther; 2010 Nov; 8(11):1609-18. PubMed ID: 21090936
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
Hsueh WA; Shojaee A; Maa JF; Neutel JM
Curr Med Res Opin; 2012 Nov; 28(11):1809-18. PubMed ID: 23072496
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.
Ram CV
Curr Med Res Opin; 2009 Jan; 25(1):177-85. PubMed ID: 19210150
[TBL] [Abstract][Full Text] [Related]
13. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
14. Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.
Erdine S
Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):31-44. PubMed ID: 22222315
[TBL] [Abstract][Full Text] [Related]
15. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor blocker combinations: from guidelines to clinical practice.
Narkiewicz K
Blood Press; 2012 Apr; 21(2):73-81. PubMed ID: 21830845
[TBL] [Abstract][Full Text] [Related]
17. Hypertension management: rationale for triple therapy based on mechanisms of action.
Neutel JM; Smith DH
Cardiovasc Ther; 2013 Oct; 31(5):251-8. PubMed ID: 23121769
[TBL] [Abstract][Full Text] [Related]
18. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Kereiakes DJ; Chrysant SG; Izzo JL; Littlejohn T; Melino M; Lee J; Fernandez V; Heyrman R
Cardiovasc Diabetol; 2012 Oct; 11():134. PubMed ID: 23110471
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg.
Schweizer J; Ulmer HJ; Benduhn H; Klebs S
Curr Med Res Opin; 2011 Jan; 27(1):131-40. PubMed ID: 21117946
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.
Volpe M; Christian Rump L; Ammentorp B; Laeis P
Clin Drug Investig; 2012 Oct; 32(10):649-64. PubMed ID: 22909147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
